Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 159

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1B
Chunk 159
---
 expenses” includes items such as the allocation of Agenus Services, depreciation and amortization expense, stock-based compensation expense, fair value adjustments and expenses related to certain foreign subsidiaries.

 83

(15) Subsequent Events Reverse Stock SplitOn January 17, 2025, the Company's stockholders approved a proposal to amend its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-10 (the “Reverse Stock Split”). On January 17, 2025, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to our Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. Pursuant to the Certificate of Amendment, the Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on January 28, 2025. As of the opening of trading on January 28, 2025, MiNK's common stock began trading on a post-split basis under CUSIP number 603693 201.All common share, per share and related information included in the accompanying financial statements and footnote disclosures have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. Nasdaq Compliance During 2024 the Company received notices from Nasdaq notifying the Company of its non-compliance with The Nasdaq Capital Market under Nasdaq Listing Rules 5550(a)(2) (the Minimum Bid Price Rule) and 5550(b)(2) (the Minimum Value of Listed Securities Rule, collectively the “Rules”).  In January 2025 the Company executed a Reverse Stock Split and in February 2025 received letters from Nasdaq notifying the Company it had regained compliance with the Rules and that it complies with the requirements for continued listing.

 84

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None. 

Item 9A. Controls and Procedures. 

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were functioning